Vardi, Nathan  | W. W. Norton & Company

30,520원  | 20240109  | 9781324074755

Vardi, Nathan  | W. W. Norton & Company

45,810원  | 20230110  | 9780393540956

A gripping business narrative and scientific thriller about what it takes to bring a wonder drug to market―and save countless lives. For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team―denied their share of the profits―went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time. In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks―and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they’re onto something big. What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi’s narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it’s so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine.

Rydzewski  | Elsevier

52,000원  | 20081013  | 9780080466170

Drug discovery increasingly requires a common understanding by researchers of the many and diverse factors that go into the making of new medicines. The scientist entering the field will immediately face important issues for which his education may not have prepared him: project teams, patent law, consultants, target product profiles, industry trends, Gantt charts, target validation, pharmacokinetics, proteomics, phenotype assays, biomarkers, and many other unfamiliar topics for which a basic understanding must somehow be obtained. Even the more experienced scientist can find it frustratingly difficult to get an overview of the many factors involved in modern drug discovery and often only after years of exploring does a whole and integrated picture emerge in the mind of the researcher. Real World Drug Discovery: A Chemist’s Guide to Biotech and Pharmaceutical Research presents this kind of map of the landscape of drug discovery. In a single, readable volume it outlines processes and explains essential concepts and terms for the recent science graduate wondering what to expect in pharma or biotech, the medicinal chemist seeking a broader and more timely understanding of the industry, or the contractor or collaborator whose understanding of the commercial drug discovery process could increase the value of his contribution to it. Key Features: - Interviews with well-known experts in many of the fields involved, giving insightful comments from authorities on many of the sub-disciplines important to cutting edge drug discovery. - Helpful suggestions gleaned from years of experience in biotech and pharma, which represents a repository drug discovery "lore" not previously available in any book. - "Periodic Table of Drugs" listing current top-selling drugs arranged by target and laid out so that structural similarities and differences are plain and clear, with regular updates available at the book's website. - Extensive use of diagrams to illustrate concepts like biotech startup models, preteomic profiling for target identification, Gantt charts for project planning, etc.

 | Ivan R. Dee Publisher

48,420원  | 20040601  | 9781566635684

In this book, Byron Sherwin briefly traces the fascinating history of the golem legend in Western culture, then shows how we can use it to navigate a safe journey--philosophically, theologically, ethically, and in public policy.

 | Wiley

259,620원  | 20040203  | 9780471465614

"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks.

 | Intervarsity

65,180원  | 20040720  | 9780830827831

What will be the greatest moral challenge facing our society throughout this century? Are we ready to face it? Editors Charles W. Colson and Nigel M. de S. Cameron, along with a panel of expert contributors, make the case in this book that the greatest watershed debates of the twenty-first century concerning ethics and public policy will surround the issue of biotechnology.

Haider, Syed Imtiaz  | Taylor & Francis

615,650원  | 20060930  | 9780849395291

Validation Standard Operating Procedures

Wisner, Stephanie A.  | BioVenture Advising, LLC

37,230원  | 20220311  | 9798885040488

Ever wonder how medicines and vaccines enter the marketplace? Why they are so expensive? Most people have heard about Theranos, a story of failure: how do biotechnology start-ups actually succeed?In Building Backwards to Biotech, author Stephanie A. Wisner demystifies the subjects of biotechnology, start-ups, and finance to answer these questions. Wisner unlocks the secrets of how to build a biotech company successfully by keeping one process always in mind: Building Backwards.

 | Springer Nature B.V.

74,480원  | 20120126  | 9789400728509

The US is currently well ahead of the rest of the world in the development and application of SB and its principles especially as they pertain to basic medical research and development. This lead is largely due to its earlier start in the academic arena. However, there is evidence of rapid development in both the UK/EU and Japan, and the gap is narrowing, particularly in the UK.

Krimsky, Sheldon (EDT)/ Shorett, Peter (EDT)  | Rowman & Littlefield

169,290원  | 20050428  | 9780742543409

 | Humana Press

465,600원  | 19940601  | 9780896033207

One comment often repeated to me by coworkers in the biotechnology industry deals with their frustration at not understanding how their particular roles fit into their company's overall scheme for developing, manufacturing, and marketing biomedical products.